11 June 2018 - Sprout gets second chance after settling suit with Valeant.
Sprout Pharmaceuticals is relaunching Addyi, the first-ever approved drug for low libido in women -- and it’s slashing the drug’s price in half.
The new price will be $400, down from $800 for a monthly prescription. The uninsured and those not covered for the treatment will pay no more than $99. It’s a rare step for a pharmaceutical company: Drugs typically go up in price on an annual basis, sometimes even twice a year.